Lars Levin - C Rad Interim Officer

All Insiders . Sweden . 
Stock . C Rad AB . Stakeholders . Insider . Lars Levin
CRAD-B Stock  SEK 28.75  0.20  0.70%   

Insider

Lars Levin is Interim Officer of C Rad AB
Age 52
Phone46 18 66 69 30
Webhttps://www.c-rad.se

C Rad Management Efficiency

The company has return on total asset (ROA) of 0.0422 % which means that it generated a profit of $0.0422 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0317 %, meaning that it generated $0.0317 on every $100 dollars invested by stockholders. C Rad's management efficiency ratios could be used to measure how well C Rad manages its routine affairs as well as how well it operates its assets and liabilities.
C Rad AB has accumulated 4.1 M in total debt with debt to equity ratio (D/E) of 3.2, implying the company greatly relies on financing operations through barrowing. C Rad AB has a current ratio of 2.44, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist C Rad until it has trouble settling it off, either with new capital or with free cash flow. So, C Rad's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like C Rad AB sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for CRAD-B to invest in growth at high rates of return. When we think about C Rad's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Simon OstergaardCellaVision AB
52
Johan LofRaySearch Laboratories AB
54
Mattias IsakssonBoule Diagnostics AB
N/A
Henrik BergentoftRaySearch Laboratories AB
49
Karen BornsteinBoule Diagnostics AB
N/A
Jesper SoderqvistBoule Diagnostics AB
57
Aishat BislievaBoule Diagnostics AB
N/A
Urban StrindlovCellaVision AB
59
Helena BorjessonBoule Diagnostics AB
N/A
JonSverre SchancheBiotage AB
66
Hkan JohanssonBonesupport Holding AB
60
Yve ThorenburgCellaVision AB
65
Tomas BlomquistBiotage AB
53
Annette ColinBoule Diagnostics AB
N/A
Maja NilssonBiotage AB
N/A
Emil BillbckBonesupport Holding AB
53
Peter KemlinRaySearch Laboratories AB
49
Petra DuprezBiotage AB
58
Kristina IngvarBonesupport Holding AB
51
Julien VeyssyCellaVision AB
40
Scott CarrBiotage AB
56
C-Rad AB , together with its subsidiaries, develops, manufactures, and sells systems with applications in radiation therapy for the treatment of cancer worldwide. C-Rad AB was founded in 2004 and is headquartered in Uppsala, Sweden. C RAD operates under Diagnostics Research classification in Sweden and is traded on Stockholm Stock Exchange. It employs 54 people. C Rad AB (CRAD-B) is traded on Stockholm Exchange in Sweden and employs 79 people.

Management Performance

Return On Equity0.0317
Return On Asset0.0422

C Rad AB Leadership Team

Elected by the shareholders, the C Rad's board of directors comprises two types of representatives: C Rad inside directors who are chosen from within the company, and outside directors, selected externally and held independent of CRAD-B. The board's role is to monitor C Rad's management team and ensure that shareholders' interests are well served. C Rad's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, C Rad's outside directors are responsible for providing unbiased perspectives on the board's policies.
Xiaodong Wang, Pres China
Tim Thurn, CEO Pres
Ivan Astralaga, Pres Americas
Hakan Axelsson, Chief Officer
Emelie Gozzi, Global Director
Priscilla Kazumba, Digital Coordinator
Lars Levin, Interim Officer

CRAD-B Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is C Rad a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity0.0317
Return On Asset0.0422
Profit Margin0.02 %
Operating Margin0.07 %
Current Valuation1.23 B
Shares Outstanding33.8 M
Shares Owned By Insiders52.18 %
Shares Owned By Institutions18.00 %
Price To Earning46.24 X
Price To Book5.61 X

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Other Information on Investing in CRAD-B Stock

C Rad financial ratios help investors to determine whether CRAD-B Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in CRAD-B with respect to the benefits of owning C Rad security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY